|Coral A. Lamartiniere, Ph.D.|
Honors and Awards:
Cotroneo, M.S., Fritz, W.A. and Lamartiniere, C.A. Dynamic profiling of estrogen receptor and epidermal growth factor signaling in the uteri of genistein- and estrogen-treated rats. Food and Chemical Toxicology. 43: 637-645, 2005.
Mentor-Marcel, R., Lamartiniere, C.A., Isam-Eldin Eltoum, I.-E., Norman M. Greenberg, N.M. and Elgavish, A. Dietary genistein improves survival and reduces expression of osteopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP). J. Nutrition. 135; 989-995, 2005.
Rowell, C., Carpenter, D.M. and Lamartiniere, C.A. Modeling Biological Variability in 2-D gel Proteomic Carcinogenesis Experiments. Journal of Proteome Research, 4:1619-1627, 2005
Rowell, C., Carpenter, D.M. and Lamartiniere, C.A. Chemoprevention of Breast Cancer, Proteomic Discovery of Genistein Action in the Rat Mammary Gland. J Nutrition Sci, 135:2953S-2959S, 2005.
Whitsett, T., Jr, Carpenter, D.M. and Lamartiniere, C.A. Resveratrol, but not EGCG, in the Diet Suppresses DMBA-induced Mammary Cancer in Rats. J. Carcinogenesis. 5: 15-25, 2006.
Whitsett T. and Lamartiniere, CA. Genistein and resveratrol: mammary cancer chemoprevention and mechanisms of action in the rat. Expert Review Anticancer Therapy. 6: 1699-1706, 2006.
Jenkins S, Rowell C, Wang J, Lamartiniere CA. Prenatal TCDD exposure predisposes for mammary cancer in rats. Reprod Toxicol. 23: 391-396, 2007.Wang, J., Eltoum, I.-E. and Lamartiniere, C.A. Genistein Chemoprevention of Prostate Cancer in TRAMP Mice. J. Carcinogenesis. 6(3): 1-10, 2007.
Harper, C, Patel, B.B., Wang, J., Eltoum, I.E., Lamartiniere, C.A. Epigallocatechin-3-Gallate Suppresses Early Stage, but not Late Stage Prostate Cancer in TRAMP mice: Mechanisms of Action. The Prostate. 67: 1576-1589, 2007.
Moral R, Wang R, Russo IH, Mailo DA, Lamartiniere CA, Russo J. The plasticizer butyl benzyl phthalate induces genomic changes in rat mammary gland after neonatal/prepubertal exposure. BMC Genomics. 2007; 8:453, 2007
Harper, C, Patel, B.B., Wang, J., Eltoum, I.E., Lamartiniere, C.A. Resveratrol Suppresses Spontaneously Developing Prostate Cancer in Transgenic Mice. Carcinogenesis. 28: 1946-1953, 2007.
Moral R, Wang R, Russo IH, Lamartiniere CA, Pereira J, Russo J. Effect of prenatal exposure to the endocrine disruptor bisphenol A on mammary gland morphology and gene expression signature. J Endocrinol. 196:101-12, 2008.
NIH - Genomic and Proteomic Biomarkers of Biological Responses to Exposure. To determine genomic and proteomic signatures in blood of pubertal girls and blood and mammary tissue of rats exposed to endocrine disruptors.
NIEHS - Study of Environment and Mammary Gland Development. To investigate the potential of environmental chemicals (TCDD, Bisphenol A, butyl benzyl phthalate) that are known endocrine disruptors, and one nutritional agent (genistein) that has been demonstrated to protect against breast cancer, when exposure occurs alone and in combination to alter mammary cancer susceptibility.
NIH - In Utero Mammary Cancer Risk with Resveratrol and TCDD. Our goal is to determine the potential of in utero exposures to resveratrol and TCDD, alone and in combination, to alter mammary gland development and differentiation, cell proliferation, protein expression, endocrine status in developing animals and susceptibility for mammary cancer in adult rats.
NIH - Center for Nutrient-Gene Interaction in Cancer Prevention. To investigate the potential of (-)-epigallocatechin-3-gallate (EGCG), resveratrol and genistein, alone and in combination to alter susceptibility for mammary cancer susceptibility and to investigate genomic and proteomic signatures following exposure to these nutrient chemicals.
DOD - Proteomic Analysis of Genistein Mammary Cancer Chemoprevention Proteomic analysis and interstitial fluid analysis of mammary glands of rats treated with DMBA and genistein.
NIEHS - In Utero TCDD Programming for Mammary Cancer. Proteomic analysis of mammary gland from rats treated in uterowith TCDD.
DOD - Polyphenols and Prostate Cancer Chemoprevention. To investigate the potential of (-)-epigallocatechin-3-gallate (EGCG), resveratrol and genistein, alone and in combination to alter susceptibility for prostate cancer susceptibility.
To contact Dr. Lamartiniere: